105 completed, 9 unknown, 7 terminated, 4 recruiting. 132 Phase 1, 25 Phase 2.
Follow Mycoses: new trials by email Literature Review of Mycoses trials Research Report on Mycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa VPM1002 Vaccine, BCG Vaccine, Placebo - Tuberculosis, HIV Infections | Phase 1 / Phase 2 | Withdrawn | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 2026-12-31 | 2026-08-17 | |
| A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes ZYG24004 1% topical film-forming formulation, ZYG24004 3% topical film-forming formulation, Placebo topical formulation - Tinea Pedis | Phase 1 | Recruiting | Sinomune Pharmaceutical Co., Ltd | 64 | 2026-07-21 | 2026-08-04 |
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections pathogen-specific CTLs - Pathogen Infection, EBV Infection | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| CD5CAR-NK Cells for Refractory Invasive Mold Disease CD5CAR-CBNK - Fungal Infection | Phase 1 | Not yet recruiting | Fundacion Clinic per a la Recerca Biomédica | 10 | 2026-05-01 | 2026-03-06 |
| Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor Topical 1 % clotrimazole twice daily 2 weeks, Oral itraconazole 200mg daily for 5 days - Pityriasis Versicolor | Phase 1 / Phase 2 | Not yet recruiting | Combined Military Hospital Abbottabad | 86 | 2026-02-02 | 2026-01-12 |
| CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia Caspofungin Acetate 50 MG, Physiologic saline - Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection | Phase 1 / Phase 2 | Recruiting | University Hospital, Tours | 100 | 2025-12-02 | 2026-10-09 |
| A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor 20% Cassia alata cream - Tinea Versicolor, Pityriasis Versicolor | Phase 1 | Recruiting | The University of The West Indies | 20 | 2025-03-01 | 2025-11-19 |
| CelAgace™ OraRinse Solution for Treatment of Candidiasis silver citrate complex and acemannan - Candidiasis, Oral | Phase 1 / Phase 2 | Unknown | CelaCare Technologies, Inc. | 15 | 2024-09-01 | 2024-02-09 |
| Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis ISOtretinoin 10 MG, excimer light, Itraconazole 200 mg - Onychomycosis | Phase 1 | Recruiting | Zagazig University | 36 | 2024-07-12 | 2026-04-23 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection BSG005 - Invasive Fungal Infection | Phase 1 / Phase 2 | Unknown | Biosergen AS | 15 | 2024-07-01 | 2025-04-06 |
| Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers CanProFem-AK - Candidosis Vaginal | Phase 1 | Completed | Industrial Microbiology LLP | 20 | 2024-06-01 | 2024-08-02 |
| Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis Nitric Oxide - Candidiasis, Oral | Phase 1 | Completed | Sanotize Research and Development corp. | 6 | 2024-01-20 | 2024-07-10 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo - Tinea Versicolor | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 430 | 2023-12-04 | 2024-03-12 |
| Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age Rezafungin Acetate - Invasive Fungal Infections | Phase 1 | Terminated | Mundipharma Research Limited | 32 | 2023-09-13 | 2025-04-06 |
| Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection | Phase 1 | Completed | Scynexis, Inc. | 5 | 2023-07-12 | 2025-08-08 |
| Efficacy of Pyodine Soaked Gelfoam vs Single Topical Application of Clotrimazole in Otomycosis Treatment Clotrimazole Cream, Povidone-Iodine - Otomycosis | Phase 1 | Completed | Rawalpindi Medical College | 90 | 2023-06-16 | 2024-04-01 |
| Pilot Study of Swift Microwave Device for Onychomycosis Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail | Phase 1 / Phase 2 | Completed | Mediprobe Research Inc. | 39 | 2023-03-27 | 2024-11-18 |
| The Anti-fungal Effect of Miconazol Versus Miconazol-Loaded Chitosan Nanoparticles Chitosan - Oral Thrush | Phase 1 | Completed | Yasmine gamil | 80 | 2023-01-10 | 2023-10-10 |
Showing 20 of 132. Sign in to see all of them.
Onychomycosis (17) · HIV Infections (15) · Acquired Immunodeficiency Syndrome (14) · Candidiasis (14) · Tinea Pedis (13) · Candidiasis, Vulvovaginal (10) · Invasive Fungal Infections (10) · Pneumonia, Pneumocystis (8) · AIDS-Related Complex (6) · AIDS-Related Opportunistic Infections (6) · Aspergillosis (6) · Candidiasis, Oral (5) · Histoplasmosis (5) · Meningitis, Cryptococcal (5)
Bacterial Infections and Mycoses (132) · Infections (131) · Skin Diseases (39) · Skin and Connective Tissue Diseases (39) · Skin Diseases, Infectious (38) · Dermatomycoses (37) · Tinea (29) · Urogenital Diseases (29) · Genital Diseases (27) · Pathological Conditions, Signs and Symptoms (24) · Immune System Diseases (22) · Virus Diseases (19) · Lung Diseases (18) · RNA Virus Infections (18)
Itraconazole (9) · Voriconazole (8) · posaconazole (7) · Fluconazole (6) · Micafungin (6) · Amphotericin B (4) · Terbinafine (4) · naftifine (4) · Dapsone (3) · butenafine (3) · liposomal amphotericin B (3) · Caspofungin (2) · Clotrimazole (2) · Leucovorin (2) · Pentamidine (2)
National Institute of Allergy and Infectious Diseases (NIAID) (15) · Sun Pharmaceutical Industries, Inc. (8) · Basilea Pharmaceutica (5) · Merck Sharp & Dohme LLC (5) · Astellas Pharma Inc (3) · Combined Military Hospital Abbottabad (3) · NovaDigm Therapeutics, Inc. (3) · Pfizer (3) · Scynexis, Inc. (3) · Stiefel, a GSK Company (3) · AM-Pharma (2) · Biosergen AS (2) · F2G Ltd (2) · GlaxoSmithKline (2) · Michael Cohen-Wolkowiez (2)
United States (59) · Netherlands (7) · United Kingdom (7) · Egypt (5) · South Korea (5) · Canada (4) · China (4) · India (4) · Australia (3) · Brazil (3) · France (3) · Pakistan (3) · Puerto Rico (3) · South Africa (3) · Spain (3)
Marc Engelhardt (5) · Dale Christensen, PhD (2) · Natalie Yantovskiy (2) · Aditya Gupta, MD,PhD (1) · Alexa B. Kimball, MD, MPH (1) · Angela Smith, M.D. (1)
PMID 36988461, PMID 15470330, PMID 16304338, PMID 18046534, PMID 20547942, PMID 20667889, PMID 20697067, PMID 20946413, PMID 22045986, PMID 22548840, PMID 23400742, PMID 23940606, PMID 24733463, PMID 25049247, PMID 25357174, PMID 26612870, PMID 26935726, PMID 28961714, PMID 29596218, PMID 29697768, PMID 30776290, PMID 30913226, PMID 31548210, PMID 31633150, PMID 32194238, PMID 32319040, PMID 32468741, PMID 32747357, PMID 33293212, PMID 34031051, PMID 34446679, PMID 34686365, PMID 34970774, PMID 35167031, PMID 36532230, PMID 36780493, PMID 36906440, PMID 37606364, PMID 38321454, PMID 38757982, PMID 38943665, PMID 39012090, PMID 39158295, PMID 39624747, PMID 39918069, PMID 39972326, PMID 40665233, PMID 41151592, PMID 41513548, PMID 9872631
2023 (2), 2008 (1), 2014 (1), 2015 (1), 2019 (1), 2025 (1), UM1AI068616 (1), UM1AI068632 (1), UM1AI106716 (1)